新辅助化疗后手术对中晚期宫颈癌的临床效果

摘要
图/表
参考文献(27)
相关文章 (15)

全文: PDF (0 KB) HTML (39 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨新辅助化疗（NACT）后手术对中晚期宫颈癌患者的临床价值。方法回顾性分析2016年6月～2019年6月在我院行宫颈癌根治术的76例中晚期宫颈癌患者的临床资料，根据术前是否接受NACT，将其分为研究组（n=38）和对照组（n=38）。通过分析研究组化疗后总有效率及两组患者手术时间、术中出血量、淋巴结转移率及脉管浸润率来评估NACT后手术对中晚期宫颈癌患者的临床价值。结果研究组患者接受NACT后均成功施行了手术，总有效率为65.79%（25/38），其中CR为0.00%（0/38），PR为65.79%（25/38），SD为34.21%（13/38），PD为0.00%（0/38）。两组患者的手术时间和术中出血量比较，差异无统计学意义（P＞0.05）；研究组患者的淋巴结转移率及脉管浸润率低于对照组，差异有统计学意义（P＜0.05）。结论 NACT后手术对中晚期宫颈癌的疗效较好，能缩小病灶大小，且不增加手术难度，为中晚期宫颈癌患者的治疗提供了又一选择。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	韩玉英
	王庆一
	康旻
	袁艳艳
	邝爱华

关键词 ：中晚期宫颈癌, 新辅助化疗, 宫颈癌根治术, 卡铂, 紫杉醇

Abstract：Objective To evaluate the clinical value after neoadjuvant chemotherapy (NACT) in patients with middle and advanced cervical cancer.Methods The clinical data of 76 patients with middle and advanced cervical cancer who underwent radical surgery of cervical cancer in our hospital from June 2016 to June 2019 were retrospectively analyzed,and divided them into research group (n=38) and control group (n=38) according to whether they received NACT before surgery.By analyzing the total effective rate after chemotherapy in the research group and the surgery time, intraoperative blood loss, lymph node metastasis rate and vascular invasion rate of the two groups of patients, the clinical value of surgery after NACT for patients with middle and advanced cervical cancer was evaluated.Results All patients in the research group successfully performed surgery after receiving NACT, with a total effective rate of 65.79% (25/38), of which CR was 0.00% (0/38), PR was 65.79% (25/38), and SD was 34.21% (13/38), PD was 0.00% (0/38).There were no significant differences in the surgery time and intraoperative blood loss between the two groups of patients (P＞0.05).The lymph node metastasis and vascular infiltration rate of the research group was lower than that of the control group,and the difference was statistically significant (P＜0.05).Conclusion NACT before radical surgery of cervical cancer has good effect on middle and advanced cervical cancer, it can reduce the size of cancer, and does not increase the difficulty of surgery, which provides another option for the treatment of patients with middle and advanced cervical cancer.

Key words： Middle and advanced cervical cancer Neoadjuvant chemotherapy Radical surgery of cervical cancer Carboplatin Paclitaxel

基金资助:广东省珠海市医学科研基金项目（20191207A01 0054）

作者简介: 韩玉英（1984-），女，江西赣州人，硕士，主治医师，妇产科教学秘书，研究方向：妇科肿瘤及妇科内分泌

引用本文:

韩玉英；王庆一；康旻；袁艳艳；邝爱华. 新辅助化疗后手术对中晚期宫颈癌的临床效果[J]. 中国当代医药, 2020, 27(23): 100-103.
HAN Yu-ying；WANG Qing-yi；KANG Min；YUAN Yan-yan；KUANG Ai-hua. Clinical effect of surgery after neoadjuvant chemotherapy on middle and advanced cervical cancer. 中国当代医药, 2020, 27(23): 100-103.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I23/100

[1]	Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[2]	Siegel RL，Miller KD，Jemal A.Cancer statistics，2018[J].CA Cancer J Clin，2018，68（1）：7-30.
[3]	Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015[J].CA Cancer J Clin，2016，66（2）：115-132.
[4]	陈渊青，邓必林.宫颈癌预防模式研究进展[J].中国妇幼健康研究，2017，28（5）：615-618.
[5]	吴绘春，杨菁.新辅助化疗在宫颈癌治疗中的应用研究[J].中国妇幼健康研究，2016，27（10）：1258-1260.
[6]	Siegel RL，Miller KD，Jemal A.Cancer Statistics，2017[J].CA Cancer J Clin，2017，67（1）：7-30.
[7]	Minig I，Patrono MG，Romero N，et al.Different strategies of treatmentforuterinecervicalcarcinomastageIB2-ⅡB[J].World J Clin Oncol，2014，5（2）：86-92.
[8]	周晖，白守民，林仲秋，等.《2018 NCCN 宫颈癌临床实践指南（第一版）》解读[J].中国实用妇科与产科杂志，2017，33（12）：1255-1261.
[9]	Therasse P，Arbuck SG，Eisenhauer EA，et al.New guidelines to evaluate the response to treatment in solid tumors[J].J Natl Cancer Inst，2000，92（3）：205-216.
[10]	Pelkofski E，Stine J，Wages NA，et al.Cervical cancer in women aged 35 years and younger[J].Clin Ther，2016，38（3）：459-466.
[11]	白璐，李雯慧，陈必良.宫颈癌新辅助化疗的现状与争议[J].现代肿瘤医学，2019，27（7）：1278-1280
[12]	李龙，赵娟，王月玲.腹腔镜下宫颈癌根治术30例临床分析[J].中国妇幼健康研究，2013，24（2）：261-263.
[13]	Colturato LF，Signorini Filho RC，Fernandes RC，et al.Lymph node micrometastases in initial stage cervical cancer and tumoral recurrence[J].Int J Gynaecol Obstet，2016，133（1）：69-75.
[14]	Ye Q，Yuan HX，Chen HL.Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients：a meta-analysis[J].J Cancer Res Clin Oncol，2013，139（11）：1887-1898.
[15]	Lapresa M，Parma G，Portuesi R，et al.Neoadjuvant chemotherapy in cervical cancer：an update[J].Expert Rev Anticancer Ther，2015，15（10）：1171-1181.
[19]	李仪.两种新辅助化疗方案治疗宫颈癌的回顾性研究[D].衡阳：南华大学，2016.
[26]	曹泽毅.减少子宫颈癌治疗后的未控和复发[J].中华妇产科杂志，2013，48（4）：302-303.
[16]	Scandurra G，Scibilia G，Banna GL，et al.Efficacy and tolerability of paclitaxel，ifosfamide，and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma[J].J Gynecol Oncol，2015，26（2）：118-124.
[17]	Gadducci A，Barsotti C，Laliscia C，et al.Dose-dense Paclitaxel-and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemo-radiotherapy in Cervical Cancer：a Preliminary Analysis[J].Anticancer Res，2017，37（3）：1249-1255.
[18]	Chen P，Jiao L，Wang DB.Squamous cell carcinoma antigen expression in tumor cells is associated with the chemosensitivity and survival of patients with cervical cancer receiving docetaxel-carboplatin-based neoadjuvant chemotherapy[J].Oncol Lett，2017，13（3）：1235-1241.
[20]	Kitagawa R，Katsumata N，Shibata T，et al.Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer：The Open-Label Randomized Phase ⅢTrial JCOG0505[J].J Clin Oncol，2015，33（19）：2129-2135.
[21]	Lorusso D，Petrelli F，Coinu A，et al.A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer[J].Gynecol Oneol，2014，133（1）：117-123.
[22]	Fei H，Ke P，Wang N，et al.An evaluation comparing Califomium252 neutron braehytherapy with neoadjuvant intraarterial embolism chemotherapy assisted surgery effect for treating advanced cervical carcinoma patients[J].Eur J Gynaecol Oncol，2015，36（4）：442-446.
[23]	Symonds RP，Gourley C，Davidson S，et al.Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer （CIRCCa）：a randomised，double-blind，placebo-controlled phase 2 trial[J].Lancet Oncol，2015，16（15）：1515-1524.
[24]	Ghezzi F，Cromi A，Ditto A，et al.Laparoscopic versus open radical hysterectomy for stage ⅠB2-ⅡB cervical cancer in the setting of neoadjuvant chemotherapy：a multi-institutional cohort study[J].Ann Surg Oncol，2013，20（6）：2007-2015.
[25]	Liang Y，Lü B，Chen X，et al.Prognostic value of pathological response to neoadjuvant chemotherapy in bulky stageⅠb2 and Ⅱa cervical squamous cell cancer patients[J].Virchows Arch，2016，468（3）：329-336.
[27]	Gupta S，Maheshwari A，Parab P，et al.Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2，ⅡA，or ⅡB squamous cervical cancer：a randomized controlled trial[J].J Clin Oncol，2018，36（16）：1548-1555.